Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$91.7077
5.55(6.1%)
as of October 30, 2026
Try our APIs with
free plan!
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
91.7077
Open
97.2614
High
98.1541
Low
90.8025
52 wk Range
37.02-98.48
Market Cap
7 247 M
P/E Ratio
69.8788
Shares Outstanding
48 837 K
Revenue
946 M
EPS
0.56
Beta
0.036
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 946 M
- EBITDA: 132 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kiniksa Pharmaceuticals Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-10-27
- EPS/Forecast: 0.32
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
Kiniksa Pharmaceuticals stock exploded 22.2% higher to US$89.20 on Wednesday after traders digested fresh Q3 2026 results. The move caps a strong recent run, yet the real story sits in the earnings pr...
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per s...
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals International, Plc – ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net produ...
Here are the major earnings before the open Tuesday
Major earnings expected before the bell on Tuesday include: * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * The Coca-Cola Company (KO [https://seekingalpha.com/symbol/KO]) * T...
Get Kiniksa Pharmaceuticals Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.